Clinical experience of QuantiFERON®-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan

British Journal of Dermatology

Volumn 164, Issue 3, 2011, Pages 553-559

  Chiu, H Y ^a   Hsueh, P R ^a   Tsai, T F ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; ETHAMBUTOL; ISONIAZID; METHOTREXATE; PYRAZINAMIDE; RIFAMPICIN; USTEKINUMAB;

ADOLESCENT; ADULT; AGED; ANALYTICAL EQUIPMENT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EXPOSURE; EXPERIENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; PSORIASIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SCREENING TEST; TAIWAN; TERTIARY HEALTH CARE; TUBERCULIN TEST; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; FEMALE; HUMANS; IMMUNOGLOBULIN G; LATENT TUBERCULOSIS; MALE; MASS SCREENING; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TAIWAN; TUBERCULIN TEST; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 79952380166     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10137.x     Document Type: Article

References (51)

1. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
2. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-7. (Pubitemid 36959191)
3. Mohan AK, Cote TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004; 39: 295-9. (Pubitemid 39050474)
4. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85. (Pubitemid 43736578)
5. Chen DY, Shen GH, Hsieh TY, et al. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008; 59: 800-6.
6. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004; 170: 59-64. (Pubitemid 38997752)
7. Lein AD, von Reyn CF, Ravn P, et al. Cellular immune responses to ESAT-6 discriminate between patients with pulmonary disease due to Mycobacterium avium complex and those with pulmonary disease due to Mycobacterium tuberculosis. Clin Diagn Lab Immunol 1999; 6: 606-9. (Pubitemid 29330751)
8. Pratt A, Nicholl K, Kay L,. Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-alpha agents: the Newcastle (UK) experience. Rheumatology (Oxford) 2007; 46: 1035-6. (Pubitemid 47062518)
9. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008; 35: 776-81. (Pubitemid 351747116)
10. Matulis G, Juni P, Villiger PM, et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 2008; 67: 84-90.
11. Sterry W, Barker J, Boehncke WH, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004; 151 (Suppl. 69): 3-17. (Pubitemid 39215184)
12. Harada N, Higuchi K, Yoshiyama T, et al. Comparison of the sensitivity and specificity of two whole blood interferon-gamma assays for M. tuberculosis infection. J Infect 2008; 56: 348-53.
13. Perlmutter A, Mittal A, Menter A,. Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol 2009; 160: 8-15.
14. Menter A,. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis 2009; 84: 14-24.
15. Doherty SD, van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 2008; 59: 209-17.
16. Su WJ,. Extensively drug-resistant tuberculosis (XDR-TB) raises challenges in TB control in Taiwan. J Formos Med Assoc 2008; 107: 827-9.
17. Centers for Disease Control, Taiwan. Statistics of Communicable Diseases and Surveillance Report in Taiwan Area, 2007. Taipei, Taiwan: Centers for Disease Control, 2009.
18. Desai N, Raste Y, Cooke NT, et al. QuantiFERON-TB Gold testing for tuberculosis in psoriasis patients commencing anti-tumour necrosis factor alpha therapy. Br J Dermatol 2008; 158: 1137-8. (Pubitemid 351521427)
19. Hernandez C, Cetner AS, Jordan JE, et al. Tuberculosis in the age of biologic therapy. J Am Acad Dermatol 2008; 59: 363-80.
20. Bowerman RJ,. Tuberculin skin testing in BCG-vaccinated populations of adults and children at high risk for tuberculosis in Taiwan. Int J Tuberc Lung Dis 2004; 8: 1228-33. (Pubitemid 39371836)
21. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005; 64: 1360-1. (Pubitemid 41206259)
22. Silva LC, Silveira GG, Arnone M, et al. Decrease in Mycobacterium tuberculosis specific immune responses in patients with untreated psoriasis living in a tuberculosis endemic area. Arch Dermatol Res 2010; 302: 255-62.
23. Tsiouri G, Gaitanis G, Kiorpelidou D, et al. Tuberculin skin test overestimates tuberculosis hypersensitivity in adult patients with psoriasis. Dermatology 2009; 219: 119-25.
24. Madariaga MG, Jalali Z, Swindells S,. Clinical utility of interferon gamma assay in the diagnosis of tuberculosis. J Am Board Fam Med 2007; 20: 540-7.
25. Ferrara G, Losi M, D'Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006; 367: 1328-34.
26. Takahashi H, Shigehara K, Yamamoto M, et al. Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration. Rheumatol Int 2007; 27: 1143-8. (Pubitemid 47373944)
27. Gogus F, Günendi Z, Karakus R, et al. Comparison of tuberculin skin test and QuantiFERON-TB Gold in tube test in patients with chronic inflammatory diseases living in a tuberculosis endemic population. Clin Exp Med 2010; 10: 173-7.
28. Laffitte E, Janssens JP, Roux-Lombard P, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. Br J Dermatol 2009; 161: 797-800.
29. Sellam J, Hamdi H, Roy C, et al. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 2007; 66: 1610-15. (Pubitemid 350205449)
30. Ferrara G, Losi M, Meacci M, et al. Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2005; 172: 631-5. (Pubitemid 41232976)
31. Ferebee SH, Mount FW,. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis 1962; 85: 490-510.
32. Comstock GW,. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999; 3: 847-50. (Pubitemid 29488035)
33. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-72. (Pubitemid 40852885)
34. Gomez-Reino JJ, Carmona L, Angel Descalzo M,. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-61. (Pubitemid 46932080)
35. Diel R, Loddenkemper R, Meywald-Walter K, et al. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008; 177: 1164-70. (Pubitemid 351717577)
36. Haldar P, Thuraisingham H, Hoskyns W, Woltmann G,. Contact screening with single-step TIGRA testing and risk of active TB infection: the Leicester cohort analysis. Thorax 2009; 64: A10.
37. Girardi E, Goletti D, Ippolito G,. Should individuals who are tuberculin skin test negative and positive to RD1-IFN-gamma assay receive preventive therapy? Am J Respir Crit Care Med 2007; 175: 198-9. (Pubitemid 46115096)
38. Ewer K, Millington KA, Deeks JJ, et al. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006; 174: 831-9. (Pubitemid 44511666)
39. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472-7. (Pubitemid 37363354)
40. Leiro V, Fernandez-Villar A, Valverde D, et al. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int 2008; 28: 835-9. (Pubitemid 351818646)
41. Sun F, Chen Y, Xiang Y, et al. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2008; 12: 994-1002.
42. Huang YS,. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opin Drug Metab Toxicol 2007; 3: 1-8.
43. Lai CC, Tan CK, Huang YT, et al. Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan. Clin Infect Dis 2008; 47: e57-63.
44. Winthrop KL, Siegel JN, Jereb J, et al. Tuberculosis associated with therapy against tumor necrosis factor alpha. Arthritis Rheum 2005; 52: 2968-74. (Pubitemid 41447075)
45. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60: 1884-94.
46. Bieber J, Kavanaugh A,. Tuberculosis and opportunistic infections: relevance to biologic agents. Clin Exp Rheumatol 2004; 22: S126-33. (Pubitemid 39328365)
47. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522-8.
48. Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372-9. (Pubitemid 38198820)
49. Aslanidis S, Pyrpasopoulou A, Douma S, et al. Is it safe to readminister tumor necrosis factor alpha antagonists following tuberculosis flare? Arthritis Rheum 2008; 58: 327-8.
50. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005; 60: 800-5.
51. Mariette X, Salmon D,. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003; 62: 791. (Pubitemid 36886422)